Adenosine and its receptors
Multiple modulatory functions and potential therapeutic targets for neurologic disease
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Glossary
- 5′NT=
- 5′-nucleotidase;
- AC=
- adenylate cyclase;
- ACh=
- acetylcholine;
- ADK=
- adenosine kinase;
- AMP=
- adenosine monophosphate;
- ATP=
- adenosine triphosphate;
- CCL=
- chemokine ligand;
- CGRP=
- calcitonin gene related peptide;
- COX-2=
- cyclooxygenase-2;
- EctoN=
- ectonucleotidases;
- ENT=
- equilibrative nucleoside transporters;
- ERK1,2=
- extracellular signal regulated kinase 1,2;
- G=
- guanine nucleotide binding protein;
- GABA=
- γ-aminobutyric acid;
- GIRK=
- G-protein gated inward rectifying potassium channels;
- IL=
- interleukin;
- NGF=
- nerve growth factor;
- NMDA=
- N-methyl-d-aspartate;
- NO=
- nitric oxide;
- PD=
- Parkinson disease;
- PLA2=
- phospholipase A2;
- PLC=
- phospholipase C;
- PLD=
- phospholipase D;
- SNc=
- substantia nigra pars compacta;
- VLPO=
- ventrolateral preoptic area.
Adenosine is a ubiquitous chemical messenger that modulates cellular activity in both the CNS and peripheral organs.1–5 Adenosine levels in the brain extracellular space increase dramatically during metabolically stressful conditions, such as ischemia, seizures, or trauma. Adenosine, acting via different receptors, modulates excitability in the CNS2–4 and has a role in mechanisms of seizure susceptibility,5,6 sleep induction,7 basal ganglia function,8 pain perception,9 cerebral blood flow,10 and respiration.11 Adenosine receptors are inhibited by caffeine and other methylxanthines and provide a potential target for treatment of cerebral ischemia,12 seizures,13 pain,9 Parkinson disease (PD),8,14 and Huntington disease.15 There are several excellent reviews on recent experimental findings and insights into adenosine signaling in the CNS,1–6,8 and on adenosine as a potential therapeutic target in neurologic disorders.5–7,12–15
ADENOSINE SIGNALING IN THE NERVOUS SYSTEM
There is tight and dynamic regulation of adenosine levels in the nervous system.1–5 All cell types contribute to the accumulation of extracellular adenosine (figure). Extracellular concentrations of adenosine are determined by the interplay between the activity of intracellular and extracellular enzymes involved in adenosine metabolism and the transport of adenosine across the cell membrane. Metabolic stress triggers the dephosphorylation of adenosine triphosphate (ATP) and formation of adenosine monophosphate (AMP), which is converted to adenosine by 5′-nucleotidase. Adenosine is then released from cells by facilitated diffusion via nucleoside transporters, the best characterized being the equilibrative nucleoside transporters (ENT).16 Adenosine may also be produced by the extracellular metabolism of ATP via a cascade of ectonucleases.2–4 The primary route of adenosine metabolism is adenosine kinase (ADK), which is expressed primarily in astrocytes (figure). The concentration of extracellular adenosine increases dramatically in the setting of metabolic stress such as hypoxia, ischemia, trauma, or seizures.2–5,12 Transport from the astrocyte is the primary source of …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.